STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
chemistry-2

Telomir Pharmaceuticals Unveils Groundbreaking Results with Telomir-1: A New Hope for Combating Oxidative Stress and Viral Infections

byLuca Blaumann
January 28, 2025
in Pharmaceuticals, Small-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Innovative drug shows potential to address aging, chronic diseases, and avian influenza through oxidative stress reversal

Telomir Pharmaceuticals (TELO), a leader in age-reversal science, has announced transformative preclinical results for its groundbreaking compound, Telomir-1. The drug demonstrated the ability to fully reverse oxidative stress caused by copper-induced Reactive Oxygen Species (ROS) in human cell lines. This breakthrough positions Telomir-1 as a promising treatment for chronic diseases and viral infections, including avian influenza (bird flu).

Oxidative stress, driven by an imbalance between free radicals and antioxidants, is a key contributor to aging and diseases such as Alzheimer’s, cancer, cardiovascular conditions, and diabetes. It accelerates cellular damage, impairs immune responses, and exacerbates the progression of viral infections like bird flu. Telomir-1’s unique mechanism not only normalizes ROS levels but also protects cells from copper-induced toxicity, addressing the root causes of these conditions.

A Breakthrough in Cellular Protection
Telomir-1’s preclinical results highlighted three key achievements:

  • Oxidative Stress Reversal: The compound fully normalized ROS levels, reversing oxidative damage.
  • Cellular Protection: It safeguarded cells against copper toxicity, maintaining cellular integrity.
  • Low-Dose Efficacy: Telomir-1’s effects were observed at doses much lower than copper levels, demonstrating a novel regulatory mechanism beyond simple chelation.

Dr. Raphael Mayer, CEO of SmartAssays, emphasized, “These findings reveal Telomir-1’s exceptional therapeutic potential. Its ability to fully reverse oxidative stress marks a significant advance in addressing age-related diseases and viral infections.”

Potential Impact Across Major Diseases
Telomir-1’s unique approach could revolutionize treatments for several conditions:

  • Wilson’s Disease: By regulating copper metabolism, it could minimize side effects associated with current therapies.
  • Alzheimer’s Disease: Telomir-1 may slow neurodegeneration by reversing copper-related oxidative damage.
  • Age-Related Macular Degeneration (AMD): Its protective effects offer hope for preserving vision.
  • Cancer: The drug could enhance cancer treatments by mitigating ROS-driven DNA damage.
  • Cardiovascular Diseases: Telomir-1 may improve vascular health by reducing oxidative stress and inflammation.

Exploring Applications in Viral Infections
Telomir is also investigating Telomir-1’s potential to mitigate oxidative stress caused by viral infections, including avian influenza. With over 868 reported bird flu cases globally and a mortality rate of 50%, the need for effective therapies is critical. Telomir-1’s ability to protect cells and reverse oxidative damage could play a pivotal role in reducing disease severity and improving patient outcomes.

Telomir Pharmaceuticals is committed to advancing Telomir-1’s development, offering hope for millions worldwide.

You might like this article:Steel Veteran Alan Kestenbaum Eyes Leadership Role at U.S. Steel

Tags: GrowthMoversNewsStock MarketTELOTelomir Pharmaceuticals
Previous Post

Steel Veteran Alan Kestenbaum Eyes Leadership Role at U.S. Steel

Next Post

General Motors Reports $6 Billion Full-Year Net Income for 2024, Prepares for a Strong 2025

Related Posts

scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

byLuca Blaumann
August 19, 2025
0

Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the...

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

byLuca Blaumann
August 14, 2025
0

Frontier technology firm posts strong top-line growth, boosts BTC portfolio, and advances R&D in energy systems and robotics KULR Technology...

chemistry-2

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

byLuca Blaumann
August 14, 2025
0

Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered...

Next Post

General Motors Reports $6 Billion Full-Year Net Income for 2024, Prepares for a Strong 2025

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

Intel Shares Surge After $2 Billion SoftBank Investment

Strategy Expands Bitcoin Holdings With $51 Million Purchase

Based on Your Interest

Aerospace & Defense

Amphenol Expands Defense Portfolio With $1 Billion Trexon Acquisition

August 18, 2025
investing
Insurance

Buffett Bet Sends UnitedHealth Shares Soaring

August 18, 2025
Small-Cap

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

August 14, 2025

Recommended

Financial Services

Berkshire Hathaway Adds New Stakes Across Healthcare, Industrials, and Real Estate

August 14, 2025
Pharmaceuticals

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

August 14, 2025
Large-Cap

Ulta and Target to End Mini-Store Partnership in 2026

August 14, 2025
Airlines

Spirit Aviation Warns of Possible Collapse as Cash Runs Low

August 13, 2025
Large-Cap

Cava Shares Plunge as Chain Cuts Same-Store Sales Outlook

August 12, 2025
Stoxpo

Follow us on social media:

Highlights

  • Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual
  • Intel Seeks More Equity Infusions Amid Mounting Financial Strains
  • Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
  • Intel Shares Surge After $2 Billion SoftBank Investment
  • Strategy Expands Bitcoin Holdings With $51 Million Purchase

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

August 21, 2025

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

August 20, 2025
scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

August 19, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?